NCT04715386

Feasibility in the Prophylaxis of Radiation Dermatitis Severity

Evaluation of Feasibility in the Prophylaxis of Radiation Dermatitis Severity in Cancer Patients

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 14 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To compare radiation dermatitis severity in irradiated skin protected by an agent verses uncovered skin based on photographs and track patient reported outcomes with use of the agent.

Conditions

• Radiation Dermatitis

Interventions

Type	Name	Description
DRUG	StrataXRT	Patients will be asked to start topical application of their allocated topical preparation on the area of skin that will be irradiated at the onset of radiation therapy, every day until skin symptoms subside (see patient information pamphlet). Apply twice per day and can be reapplied as skin symptoms arise or as needed. The amount of StrataXRT provided to each patient will be recorded throughout treatment.

Timeline

• Start date: 2020-06-22
• Primary completion: 2024-01-30
• Completion: 2024-01-30
• First posted: 2021-01-20
• Last updated: 2024-02-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study